Efficacy and limitations of oral inotropic agents for the treatment of chronic heart failure: A single center cross-sectional observational study

International Heart Journal

Volumn 54, Issue 2, 2013, Pages 75-81

  Murai, Koji ^b   Seino, Yoshihiko ^a   Kimata, Nakahisa ^a   Inami, Toru ^a   Murakami, Daisuke ^a   Abe, Junko ^a   Yodogawa, Kenji ^a   Maruyama, Mitsunori ^a   Takano, Masamichi ^a   Ohba, Takayoshi ^a   Ibuki, Chikao ^a   Mizuno, Kyoichi ^b  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Beta blocker; Denopamine; Docarpamine; Pimobendan

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DENOPAMINE; DOCARPAMINE; INOTROPIC AGENT; PIMOBENDAN;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; EMERGENCY WARD; FEMALE; HEART DEATH; HEART FAILURE; HOSPITALIZATION; HUMAN; JAPAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; CARDIOTONIC AGENTS; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84875884560     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.54.75     Document Type: Article

References (38)

1. Kumada T, Kawai C, Sakuma A. Evaluation of new oral dopamine (TA-870) in patients with circulatory failure under drip infusion dopamine-multiclinic double-blind group comparative study versus dopamine hydrochloride infectable-. Rinsyo to Iyaku 1991; 7: 1521-41. (Japanese)
2. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation 1992; 85: 942-9.
3. Sasayama S, Asanoi H, Kihara Y, et al. Clinical effects of longterm administration of pimobendan in patients with moderate congestive heart failure. Heart Vessels 1994; 9: 113-20.
4. Katz SD, Kubo SH, Jessup M, et al. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J 1992; 123: 95-103.
5. Ikeda M, Sakuma A, Kawai T, Kumada T. Efficacy of new oral inotropic agent "denopamine" (TA-064) for heart failure (double blind study). Igaku no Ayumi 1987; 140: 839-64.
6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
7. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
8. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8.
9. Yoshikawa T, Baba A, Suzuki M, et al. Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group. Am J Cardiol 2000; 85: 1495-7.
10. Fujino K, Sperelakis N, Solaro RJ. Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res 1988; 63: 911-22.
11. van Meel JC, Entzeroth M, Redemann N, Haigh RM. Effects of pimobendan and its metabolite on myofibrillar calcium responsiveness and ATPase activity in the presence of inorganic phosphate. Arzneimittelforschung 1995; 45: 136-41.
12. Holubarsch C. New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors. Cardiology 1997; 88 Suppl 2: 12-20.
13. Remme WJ, Wiesfeld AC, Look MP, Kruyssen HA. Hemodynamic effects of intravenous pimobendan in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1989; 14 Suppl 2: S41-4.
14. Permanetter B, Sebening H, Hartmann F, Klein G. Acute effects of intravenous UD-CG 115 BS (pimobendan) on the cardiovascular system and left ventricular pump function. J Cardiovasc Pharmacol 1989; 14 Suppl 2: S36-40.
15. Hasenfuss G, Holubarsch C, Heiss HW, Just H. Influence of UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Am Heart J 1989; 118: 512-9.
16. Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76: 223-31.
17. Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study). Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J 2002; 66: 149-57.
18. Yoshikawa M, Endo H, Komatsu K, Sugawara Y, Takaiti O. Metabolism of a new orally active dopamine prodrug, N-(N-acetyl-Lmethionyl)-O, O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine after oral administration to rats and dogs. J Pharmacobiodyn 1990; 13: 246-53.
19. Yamaguchi I, Nishiyama S, Akimoto Y, Yoshikawa M, Nakajima H. A novel orally active dopamine prodrug TA-870. I. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats. J Cardiovasc Pharmacol 1989; 13: 879-86.
20. Nishiyama S, Yamaguchi I, Akimoto Y, Yoshikawa M, Nakajima H. A novel orally active dopamine prodrug TA-870. II. Evidence that TA-870 is a dopamine prodrug. J Cardiovasc Pharmacol 1989; 14: 175-83.
21. Hosoda S, Takano T, Morooka N, et al. The effects of oral dopamine, clinical study of prodrug (docarpamine) Rinsyo to Kenkyu 1990; 1990: 3206-18. (Japanese)
22. Ogawa H, Kusugawa R, Matsui S, et al. Weaning from intravenous dopamine by TA-870 (docarpamine), check the efficacy and appropriate dose of docarpamine.-multicenter trial. Yakuri to Chiryo 1991; 19: 1907. (Japanese)
23. Kanzawa T, Ikeda N. Efficacy or appropriate dose of TA-870 (docarpamine) for insufficient circulation.-assessment of weaning from intravenous inotrope, dopamine and dobutamine. Kiso to Rinsyo 1991; 25: 2289-304. (Japanese)
24. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-23.
25. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term betablocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990; 88: 223-9.
26. Yoshikawa T, Handa S, Anzai T, et al. Early reduction of neurohumoral factors plays a key role in mediating the efficacy of betablocker therapy for congestive heart failure. Am Heart J 1996; 131: 329-36.
27. Eichhorn EJ, McGhie AL, Bedotto JB, et al. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol 1991; 67: 67-73.
28. Sugiyama S, Hattori M, Miyazaki Y, Nagai S, Ozawa T. Mechanism of antiarrhythmic action of beta-blocking agents. J Electrocardiol 1985; 18: 169-73.
29. Szabó BM, Crijns HJ, Wiesfeld AC, et al. Predictors of mortality in patients with sustained ventricular tachycardias or ventricular fibrillation and depressed left ventricular function: importance of beta-blockade. Am Heart J 1995; 130: 281-6.
30. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the longterm effects of metoprolol versus carvedilol. Circulation 2000; 102: 546-51.
31. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 2001; 81: 141-9.
32. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94: 2817-25.
33. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-75.
34. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators. Br Heart J 1994; 72: 226-30.
35. Krell MJ, Kline EM, Bates ER, et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986; 112: 787-91.
36. Lee JC, Downing SE. Cyclic AMP and the pathogenesis of myocardial injury. Res Commun Chem Pathol Pharmacol 1980; 27: 305-18.
37. Ebbesen P. Myocardial degeneration in mice treated with dibutyryl cyclic AMP and/or theophylline. Virchows Arch A Pathol Anat Histol 1976; 372: 89-95.
38. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290: 2581-7.